相关实验视频

Updated: May 6, 2026

Adapting 3' Rapid Amplification of CDNA Ends to Map Transcripts in Cancer

Adapting 3' Rapid Amplification of CDNA Ends to Map Transcripts in Cancer

Published on: March 28, 2018

单细胞转录组分析和机器学习将ATAD3A确定为稳定线粒体内质网膜的关键基因,促进膀癌的进展

Henghui Zhang¹, Sisi Han², Zhengming Su¹

¹Department of Urology, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510515, China.

Journal of translational medicine

|February 20, 2026

概括

线粒体关联的内质网膜 (MAM) 与膀癌 (BCa) 抗化疗有关. ATAD3A被确定为促进瘤生长和抗性的关键基因,提供潜在的治疗标.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
基因组学就是基因组学.

背景情况:

线粒体相关的细胞内膜网膜 (MAM) 在癌症中至关重要,但它们在膀癌 (BCa) 中的作用尚不清楚.
研究MAM的功能对于了解BCa进展和治疗耐药性至关重要.

研究的目的:

探索MAM在膀癌中的作用.
确定BCa的预后生物标志物,并研究它们与化疗耐药性的联系.
阐明在BCa.中MAM的功能背后的分子机制.

主要方法:

对RNA测序和单细胞转录组数据的全面分析.
使用LASSO-Cox回归,Kaplan-Meier和ROC分析构建和验证一个MAM风险特征模型.
使用了细胞通信分析 (CellChat),免疫细胞量化 (CIBERSORT),机器学习和空间转录学. ATAD3A的功能在体外和体内得到了验证.

主要成果:

开发了一个强大的MAM预后签名,预测BCa患者的不良结果.
高MAM分数与免疫抑制性瘤微环境和化疗耐药性相关.
ATAD3A被确定为预测西斯和抗性的关键基因,对BCa治疗至关重要. ATAD3A敲击抑制了瘤的生长.

结论:

MAM与BCa化疗耐药性显著相关.
ATAD3A是一种预后生物标志物,也是膀癌的潜在治疗点.
机器学习和多omics分析揭示了ATAD3A在维护MAM完整性和促进化学抵抗方面的作用.

关键词:

ATAD3A ATAD3A 是一个膀癌是一种癌症.机器学习机器学习线粒体关联的内细胞网膜膜.一个单细胞的单细胞.

更多相关视频

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

Published on: September 13, 2018

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...